Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 107

Results For "regulatory"

1129 News Found

CRISIL positive on Krishna Institute of Medical Sciences
News | August 25, 2021

CRISIL positive on Krishna Institute of Medical Sciences

CRISIL Ratings has revised its outlook on the long term ratings of Krishna Institute Of Medical Sciences Limited (KIMS) to 'Positive' from 'Stable' while reaffirming the ratings at 'CRISIL AA-/CRISIL A1+'


Pfizer to acquire Trillium Therapeutics
Biotech | August 24, 2021

Pfizer to acquire Trillium Therapeutics

Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells


Lupin launches Luforbec to treat asthma & COPD in UK
News | August 24, 2021

Lupin launches Luforbec to treat asthma & COPD in UK

It is the first branded generic alternative to Fostair 100/6 pMDI


DBT-BIRAC supported India’s first m-RNA vaccine gets nod for Phase II/III trial
Biotech | August 24, 2021

DBT-BIRAC supported India’s first m-RNA vaccine gets nod for Phase II/III trial

CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study


Pfizer receives EC approval for XEIJANZ
Biotech | August 23, 2021

Pfizer receives EC approval for XEIJANZ

XELJANZ is the first and only Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular JIA and juvenile PsA and has received regulatory approval in four indications in the European Union, the most of any JAK inhibitor


Aurobindo Pharma calls off its acquisition of Cronus Pharma
News | August 21, 2021

Aurobindo Pharma calls off its acquisition of Cronus Pharma

The acquisition was expected to be completed in eight weeks, and it would have provided it with a foothold in the US $ 48 billion global animal health market


AstraZeneca-Sputnik V combination demonstrates high immunogenicity profile: RDIF
Biotech | August 20, 2021

AstraZeneca-Sputnik V combination demonstrates high immunogenicity profile: RDIF

Preliminary data from the first 20 participants in Azerbaijan show antibodies to the SARS-CoV-2 virus spike protein (S-protein) elicited in 100% of cases


FDA grants breakthrough device designation to Impella ECP, the world’s smallest heart pump
Drug Approval | August 19, 2021

FDA grants breakthrough device designation to Impella ECP, the world’s smallest heart pump

It measures 9 French (3 millimetres) in diameter upon insertion and removal from the body. While in the heart, it expands to support the heart’s pumping function, providing flow greater than 3.5 L/min


Test At Home (TAH), offers convenient saliva-based testing for Covid-19
Drug Approval | August 18, 2021

Test At Home (TAH), offers convenient saliva-based testing for Covid-19

TAH is now undergoing regulatory clearance and final quality control procedures for the swab deployment in India, EU, Singapore, UK, US, Australia and others for COVID-19 testing


Pfizer & BioNTech submits Phase 1 data to US FDA for booster dose Covid-19
Biotech | August 17, 2021

Pfizer & BioNTech submits Phase 1 data to US FDA for booster dose Covid-19

The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.